Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Pediatric liver transplantation is an important modality for treating biliary atresia. The overall survival (OS) rate of pediatric liver transplantation has significantly improved compared with that of 20 years ago, but it is still unsatisfactory. The anesthesia strategy of maintaining low central venous pressure (CVP) has shown a positive effect on prognosis in adult liver transplantation. However, this relationship remains unclear in pediatric liver transplantation. Thus, this study was conducted to review the data of pediatric living-donor liver transplantation to analyze the associations of different CVP levels with the prognosis of recipients.
Methods: This was a retrospective study and the patients were divided into two groups according to CVP levels after abdominal closure: low CVP (LCVP) (≤ 10 cmHO, n = 470) and high CVP (HCVP) (> 10 cmHO, n = 242). The primary outcome measured in the study was the overall survival rate. The secondary outcomes included the duration of mechanical ventilation in the intensive care unit (ICU), length of stay in the ICU, and postoperative stay in the hospital. Patient demographic and perioperative data were collected and compared between the two groups. Kaplan-Meier curves were constructed to determine the associations of different CVP levels with the survival rate.
Results: In the study, 712 patients, including 470 in the LCVP group and 242 in the HCVP group, were enrolled. After propensity score matching, 212 pairs remained in the group. The LCVP group showed a higher overall survival rate than the HCVP group in the Kaplan-Meier curves and multivariate Cox regression analyses (P = 0.018), and the HCVP group had a hazard ratio of 2.445 (95% confidence interval, 1.163-5.140).
Conclusion: This study confirmed that a low-CVP level at the end of surgery is associated with improved overall survival and a shorter length of hospital stay.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12519-022-00632-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Post-recurrence Survival After Liver Transplantation for Hepatocellular Carcinoma.
Transplantation
September 2025
General Surgery and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Background: Mortality after liver transplantation (LT) for hepatocellular carcinoma (HCC) is mainly driven by HCC recurrence. We sought to determine whether post-recurrence survival (PRS) has improved during the last 2 decades.
Methods: Using the Scientific Registry of Transplant Recipients, we included all patients who underwent LT for HCC between 2003 and 2020 and experienced HCC recurrence.
Fever, cytopenia, and splenomegaly in a liver transplant patient.
Am J Transplant
September 2025
Section of Abdominal Transplantation, Department of Surgery, Washington University in St. Louis, St. Louis, Missouri, USA. Electronic address:
Empagliflozin alleviates hepatic ischemia-reperfusion injury by inhibiting c-Myc through the JAK1-STAT3 signaling pathway.
Int Immunopharmacol
September 2025
Department of Hepatobiliary and Hydatid Disease, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi, China. Electronic address:
Hepatic ischemia-reperfusion injury (HIRI) is a critical factor affecting the outcomes of liver surgeries, with inflammation and apoptosis playing pivotal roles in its pathogenesis. Empagliflozin, an anti-diabetic drug, has demonstrated hepatoprotective effects in various liver diseases, but its role in HIRI remains unclear. This study aimed to explore the protective mechanisms of empagliflozin against HIRI.
View Article and Find Full Text PDFFirst use of imlifidase desensitization in a highly sensitized heart and liver transplant candidate: A case report.
Hum Immunol
September 2025
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Heart transplant candidates that are highly sensitized against human leukocyte antigens (HLA) face ongoing challenge in finding immunologically compatible donors. Desensitization strategies aimed at reducing HLA antibody titers have variable success rates. Imlifidase, a novel immunoglobulin G-degrading enzyme derived from Streptococcus pyogenes has been successfully used to eliminate pre-formed antibodies in sensitized kidney transplant recipients.
View Article and Find Full Text PDFEmbracing Imperfect Tools to Decode AKI in Decompensated Cirrhosis.
Dig Dis Sci
September 2025
Department of Medicine, University of California-San Francisco, San Francisco, CA, USA.